Chahra Louafi
VP, Supervisory Board @ Inserm Transfert Initiative
Maisons-alfort, France
Chahra Louafi is a Series A investor at Inserm Transfert Initiative in Maisons-alfort focused on Biotechnology and Medical. Chahra Louafi is Director and Head of Investment Fund biotherapy and rare diseases Bpifrance (eg CDC Entreprises). Before joining CDC Entreprises in 2001, she was in charge of project development and entrepreneurship in a private incubator specializing in biotechnology. Within CDC Entreprises, attached to the New Developments Team, Chahra wasresponsible for investments in fund of funds dedicated to priming and technology transfer operations. She is Vice-President of the Supervisory Board of Inserm Transfert Initiative and member of the supervisory board of Cape Decisive Management. She serves on the governing bodies of DBV Technologies, Sensorion, Eyevensys, MEDday and Pixium Vision.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 20%
Last updated:
For AI agents: llms.txt
Industries Chahra Louafi invests in
Stages Chahra Louafi invests in
Countries Chahra Louafi invests in
Investment Focus
Industry
- Biotechnology 3 (60%)
- Medical 2 (40%)
- Health Care 2 (40%)
- Therapeutics 2 (40%)
- Information Technology 2 (40%)
Stage
- Series A 2 (40%)
- Seed 1 (20%)
- Series B 1 (20%)
- Funding Round 1 (20%)
Country
- France 3 (60%)
- Switzerland 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Implicity
|
Implicity is a developer of a Saas-based remote monitoring platform designed to provide smart monitoring of connected cardiac prostheses. The company's platform sorts and summarizes data of patients with connected pacemakers and defibrillators with the help of an artificial intelligence module and determines the criticality of each alerttaking into account the medical context of the patient, enabling cardiologists and healthcare professionals to automate the remote monitoring of their patients and get patients' telepulse on a single platform. | $23M / Series A / Apr 27, 2022 | |
Lucine
|
Lucine has the ambition to transform and improve patient’s health. Their main therapeutic area is pain. The product, a digital therapeutic is able to relieve patient’s pain in 5 minutes through active substances allowing an analgesic neurostimulation. Customized, their solution is adapted to each patient thanks to an instantaneous measurement andanalysis of the pain by facial, vocal and postural recognition. | $5.8M / Seed / Nov 18, 2020 | |
Therachon
|
Therachon is a global biotechnology company focused on developing medicines for rare, genetic diseases that currently have no available treatments. The company’s lead pipeline candidate, TA-46, is a novel protein therapy in development for achondroplasia, the most common form of short-limbed dwarfism. Therachon is headquartered in Basel,Switzerland, with research labs in Nice, France. | $60M / Series B / Aug 09, 2018 | |
|
Therachon
|
Therachon is a global biotechnology company focused on developing medicines for rare, genetic diseases that currently have no available treatments. The company’s lead pipeline candidate, TA-46, is a novel protein therapy in development for achondroplasia, the most common form of short-limbed dwarfism. Therachon is headquartered in Basel,Switzerland, with research labs in Nice, France. | $5M / Series A / Jan 06, 2017 | |
Sensorion
|
Sensorion, a Clapiers, France-based biopharmaceutical company specifically dedicated to the development of innovative and targeted therapeutic solutions to treat vestibular deficits. | $4.2M / Jan 21, 2015 |
Co-Investors
About Inserm Transfert Initiative
Inserm Transfert Initiative is a seed stage life science vehicle currently managing about €4.2M for the financing of new biotech companies. Inserm Transfert Initiative is the new investment vehicle of INSERM in France.
Inserm Transfert Initiative Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Jean-Michel Gauthier
CSO - Member of the Executive management Board (Directoire)
|
|||
|
Chahra Louafi
VP, Supervisory Board
|
|||
3 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Chahra Louafi invest in?
Chahra Louafi invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Seed stage. Most of the 5 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Chahra Louafi last invest?
The most recent investment recorded for Chahra Louafi closed in Apr 2022. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
